Literature DB >> 6394579

Vancomycin therapy of severe staphylococcal infections.

W M Kirby.   

Abstract

Vancomycin, introduced clinically about 30 years ago, has been used widely over the past decade because of the increasing incidence of methicillin-resistant staphylococci. Its bactericidal action, high and prolonged blood levels, the lack of development of resistant strains, and decreased adverse reactions with the more purified preparation now available, make it an excellent agent for staphylococcal infections due to strains resistant to the beta-lactam antibiotics. Recent articles reviewing the efficacy of vancomycin are summarized.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6394579     DOI: 10.1093/jac/14.suppl_d.73

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Antimicrobial resistance of Staphylococcus aureus: genetic basis.

Authors:  B R Lyon; R Skurray
Journal:  Microbiol Rev       Date:  1987-03

2.  Systemic antibacterial activity of novel synthetic cyclic peptides.

Authors:  Véronique Dartois; Jorge Sanchez-Quesada; Edelmira Cabezas; Ellen Chi; Chad Dubbelde; Carrie Dunn; Juan Granja; Colleen Gritzen; Dana Weinberger; M Reza Ghadiri; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis.

Authors:  Y A Hekster; T B Vree; C M Weemaes; J J Rotteveel
Journal:  Pharm Weekbl Sci       Date:  1986-12-12

4.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

5.  Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment.

Authors:  Jon-David Schwalm; Philippe El-Helou; Christine H Lee
Journal:  Can J Infect Dis       Date:  2004-03

6.  Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis.

Authors:  Yuko Shimamoto; Tsuyoshi Fukuda; Kazuhiko Tanaka; Katsuya Komori; Daikai Sadamitsu
Journal:  Intensive Care Med       Date:  2013-04-20       Impact factor: 17.440

7.  Composition and antimicrobic resistance of skin flora in hospitalized and healthy adults.

Authors:  E L Larson; K J McGinley; A R Foglia; G H Talbot; J J Leyden
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

8.  Mechanisms of vancomycin-induced histamine release from rat peritoneal mast cells.

Authors:  Y Horinouchi; K Abe; K Kubo; M Oka
Journal:  Agents Actions       Date:  1993-09

9.  Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters.

Authors:  S R Smith; J Cheesbrough; R Spearing; J M Davies
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

10.  Decreased vancomycin clearance in patients with congestive heart failure.

Authors:  Yuko Shimamoto; Tsuyoshi Fukuda; Shinjiro Tominari; Kyoko Fukumoto; Kazuyuki Ueno; Min Dong; Kazuhiko Tanaka; Takuma Shirasaka; Katsuya Komori
Journal:  Eur J Clin Pharmacol       Date:  2012-07-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.